We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Read MoreHide Full Article
Key Takeaways
HIMS will acquire YourBio Health to enhance its user-focused blood sampling capabilities.
The buyout adds TAP and HALO tech to HIMS' portfolio, offering bladeless, pain-free blood sampling.
The move supports HIMS' broader push into routine diagnostics and personalized healthcare tools.
Yesterday, Hims & Hers Health, Inc. (HIMS - Free Report) entered into a definitive agreement to acquire Boston-based YourBio Health, Inc. The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions.
YourBio’s, a renowned name in capillary whole blood sampling technology, TAP device, built on HALO technology, uses bladeless microneedles to produce high-quality capillary blood samples in seconds. This reduces the pain or complexity of traditional methods, like fingerstick or venipuncture.
The latest buyout is expected to significantly aid Hims & Hers in its efforts to enhance the overall blood collection experience through YourBio’s advanced blood sampling devices.
Trend in HIMS Stock Following the News
Following the announcement, shares of the company gained nearly 0.2% in overnight trading.
Historically, the company has gained a high level of synergies from its various deals. We expect market sentiment on the stock to remain positive around this announcement, too.
Hims & Hers currently has a market capitalization of $8.44 billion. It has an earnings yield of 1.3%, better than the industry’s negative yield. In the last reported quarter, HIMS delivered a negative earnings surprise of 33.3%.
Rationale Behind Hims & Hers’ Latest Acquisition
Per Hims & Hers, the acquisition is expected to enable it to bring into its portfolio the most advanced, pain-free blood sampling technology to date and proceed toward achieving user-centric blood sampling.
YourBio’s management believes its HALO and TAP technologies have the potential to change how people engage with routine blood collection — replacing long waits and painful needles with a far more convenient, user-friendly experience.
Industry Prospects in Favor of HIMS
Per a report by Grand View Research, the global capillary blood collection devices market was estimated at $2.13 billion in 2024 and is anticipated to reach $3.52 billion by 2030 at a CAGR of 8.8%. Factors like the rising availability of Point-of-Care diagnostics and the increasing prevalence of chronic diseases, such as diabetes, are likely to drive the market.
Given the market potential, the latest acquisition is expected to provide a significant boost to Hims & Hers’ business.
Hims & Hers’ Notable Deals
In July, Hims & Hers announced its plans to bring its affordable, holistic weight loss program to Canada. The company’s entry into Canada will likely come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care.
In June, Hims & Hers announced its agreement to acquire ZAVA, a digital health platform in Europe. The deal, which marks a significant step toward its global expansion, will likely expand HIMS’ footprint in the U.K. and will officially launch the company into Germany, France and Ireland, with more markets anticipated soon.
HIMS’ Share Price Performance
Shares of the company have gained 20.7% in the past year against the industry’s 0.5% decline. The S&P 500 has gained 15.6% in the same time frame.
Image Source: Zacks Investment Research
Hims & Hers’ Zacks Rank & Key Picks
Currently, HIMS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Solventum Corporation (SOLV - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Solventum, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 1.6%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Solventum’s shares have gained 22.1% compared with the industry’s 0.9% rise in the past year.
Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.7%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.3%.
Intuitive Surgical has rallied 4.1% compared with the industry’s 0.4% gain in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 68.4% compared with the industry’s 0.4% gain in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Key Takeaways
Yesterday, Hims & Hers Health, Inc. (HIMS - Free Report) entered into a definitive agreement to acquire Boston-based YourBio Health, Inc. The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions.
YourBio’s, a renowned name in capillary whole blood sampling technology, TAP device, built on HALO technology, uses bladeless microneedles to produce high-quality capillary blood samples in seconds. This reduces the pain or complexity of traditional methods, like fingerstick or venipuncture.
The latest buyout is expected to significantly aid Hims & Hers in its efforts to enhance the overall blood collection experience through YourBio’s advanced blood sampling devices.
Trend in HIMS Stock Following the News
Following the announcement, shares of the company gained nearly 0.2% in overnight trading.
Historically, the company has gained a high level of synergies from its various deals. We expect market sentiment on the stock to remain positive around this announcement, too.
Hims & Hers currently has a market capitalization of $8.44 billion. It has an earnings yield of 1.3%, better than the industry’s negative yield. In the last reported quarter, HIMS delivered a negative earnings surprise of 33.3%.
Rationale Behind Hims & Hers’ Latest Acquisition
Per Hims & Hers, the acquisition is expected to enable it to bring into its portfolio the most advanced, pain-free blood sampling technology to date and proceed toward achieving user-centric blood sampling.
YourBio’s management believes its HALO and TAP technologies have the potential to change how people engage with routine blood collection — replacing long waits and painful needles with a far more convenient, user-friendly experience.
Industry Prospects in Favor of HIMS
Per a report by Grand View Research, the global capillary blood collection devices market was estimated at $2.13 billion in 2024 and is anticipated to reach $3.52 billion by 2030 at a CAGR of 8.8%. Factors like the rising availability of Point-of-Care diagnostics and the increasing prevalence of chronic diseases, such as diabetes, are likely to drive the market.
Given the market potential, the latest acquisition is expected to provide a significant boost to Hims & Hers’ business.
Hims & Hers’ Notable Deals
In July, Hims & Hers announced its plans to bring its affordable, holistic weight loss program to Canada. The company’s entry into Canada will likely come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care.
In June, Hims & Hers announced its agreement to acquire ZAVA, a digital health platform in Europe. The deal, which marks a significant step toward its global expansion, will likely expand HIMS’ footprint in the U.K. and will officially launch the company into Germany, France and Ireland, with more markets anticipated soon.
HIMS’ Share Price Performance
Shares of the company have gained 20.7% in the past year against the industry’s 0.5% decline. The S&P 500 has gained 15.6% in the same time frame.
Image Source: Zacks Investment Research
Hims & Hers’ Zacks Rank & Key Picks
Currently, HIMS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Solventum Corporation (SOLV - Free Report) , Intuitive Surgical, Inc. (ISRG - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Solventum, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 1.6%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Solventum’s shares have gained 22.1% compared with the industry’s 0.9% rise in the past year.
Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 15.7%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.3%.
Intuitive Surgical has rallied 4.1% compared with the industry’s 0.4% gain in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 68.4% compared with the industry’s 0.4% gain in the past year.